Reduced coronary flow reserve in familial hypercholesterolemia

Journal of Nuclear Medicine

Volumn 37, Issue 12, 1996, Pages 1937-1942

  Yokoyama, Ikuo ^a   Murakami, Toru ^a   Ohtake, Tohru ^a   Momomura, Shin Ichi ^a   Nishikawa, Junichi ^a   Sasaki, Yasuhito ^a   Omata, Masao ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

coronary flow reserve; dipyridamole; familial hypercholesterolemia; myocardial blood flow; PET

Indexed keywords

AMMONIA; DIPYRIDAMOLE;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; CALCULATION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BLOOD FLOW; DIAGNOSTIC ACCURACY; DISEASE PREDISPOSITION; EARLY DIAGNOSIS; FEMALE; HEART MUSCLE BLOOD FLOW; HUMAN; HYPERCHOLESTEROLEMIA; IMAGE ANALYSIS; LIPID METABOLISM; MALE; MORTALITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

AMMONIA; CHOLESTEROL; CORONARY ARTERIOSCLEROSIS; CORONARY CIRCULATION; DIPYRIDAMOLE; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; NITROGEN RADIOISOTOPES; TOMOGRAPHY, EMISSION-COMPUTED; VASODILATOR AGENTS;

EID: 0030479643     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Goldstein JL, Dana SE, Brunschede GY, Brown MS. Genetic heterogeneity in familial hypercholesterolemia: evidence for two different mutations affecting functions of low-density lipoprotein receptor. Proc Natl Acad Sci USA 1975;72:1092-1096.
2. Mabuchi H, Tanami R, Haba T, et al. Cause of death in patients with familial hypercholesterolemia. Atherosclerosis 1986;61:1-6.
3. Mabuchi H, Koizumi J, Shimizu M, Takeda R, Hokuriku FH, CHD Study Group. Development of coronary heart disease in familial hypercholesterolemia. Circulation 1989;89:225-232.
4. Heiberg A. The risk of atherosclerotic vascular disease in subjects with xanthomatosis. Acta Med Scand 1975;198:249-261.
5. Beaumont V, Jacotot B, Beaumont JL. Ischemic disease in men and women with familial hypercholesterolemia and xanthomatosis: a comparative study of genetic and environmental factors in 274 heterozygous cases. Atherosclerosis 1976;24:441-450.
6. Jensen J, Blankenhom DH, Kornerup V. Coronary artery disease in familial hypercholesterolemia. Circulation 1967;36:77-82.
7. Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with type II hyperlipoproteinemia. Circulation 1974;49:476-488.
8. Kwilerovichl PO Jr, Levy RI, Fredrickson DS. Neonatal diagnosis of familial type II hyperlipoproteinemia. Lancet 1973;1:118-121.
9. Slach J. Risk of ischemic heart disease in familial hyperlipoproteinemic states. Lancet 1969;2:1380-1383.
10. Gould KL, Lipscomb K. Effects of coronary stenoses on coronary flow reserve and resistance. Am J Cardiol 1974;34:48.
11. Dayanikli F, Grambow D, Muzil O, Mosca L, Rubenfire M, Schwaiger M. Early detection of abnormal coronary flow reserve in asymptomatic men at high risk for coronary artery disease using positron emission tomography. Circulation 1994;90: 808-817.
12. Krivokapitch J, Smith GT, Huang SC, et al. Nitrogen-13-ammonia myocardial imaging at rest and with exercise in normal volunteers. Circulation 1989;80:1328-1337.
13. 13N-ammonia and dynamic positron emission tomographic imaging. J Am Coll Cardiol 1990;15:1032-1042.
14. Gould KL. Reversal of coronary atherosclerosis. Clinical promise as the basis for noninvasive management of coronary artery disease. Circulation 1994;90:1558-1571.
15. Nitenberg A, Valensi P, Sachs R, Dalim M, Aptecar E, Attali JR. Impairment of coronary vascular reserve and Ach-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal ventricular systolic function. Diabetes 1993;32:1017-1023.
16. Uren NG, Crake T, Leffery DC, Silva R, Gavies GJ, Maseri A. Reduced coronary vasodilator function in infarcted and normal myocardium after myocardial infarction. N Engl J Med 1994;331:222-227.
17. Cohen RA, Zitnay KM, Haudenshild CC, Cunningham LD. Loss of selective endothelial cell vasoactive functions caused by hypercholesterolemia in pig coronary arteries. Circ Res 1988;63:903-910.
18. Osborne JA, Siegman MJ, Sedar AW, Mooers SU, Lefer AM. Lack of endothelium-dependent relaxation in coronary resistance arteries of cholesterol-fed rabbits. Am J Physiol 1989;256:C591-C597.
19. Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolemic patients by L-arginine. Lancet 1991;338:1546-1549.
20. Zeiher AM, Drexler H, Wollschlaeger H, Just H. Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991;83:391-401.
21. Drexler H, Zeiher AM. Endothelial function in human coronary arteries in vivo. Focus on hypercholesterolemia. Hypertension 1991:18(4 suppl):1190-1199.
22. Sellke FW, Armstrong ML, Harrison DG. Endothelium-dependent vascular relaxation is abnormal in the coronary microcirculation of atherosclerotic patients. Circulation 1990;81:1586-1593.
23. Casino PR, Kilcoyne CM, Quyyumi AA, Hoeg JM, Panza JA. The role of nitric oxide in endothelium-dependent vasodilation of hypercholesterolemic patients. Circulation 1993;88:2541-2547.
24. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-derived relaxing factor in human forearm circulation in vivo: blunted response in essential hypertension. N Engl J Med 1990;323:22-27.
25. Sakuma I, Akaishi Y, Fukao M, Yasuda H. Dipyridamole potentiates anti-aggregating and vaso-relaxing effects of endothelium-derived relaxing factor by the inhibition of cyclic GMP phosphodiesterase [Abstract]. J Pharmacobiol-Dyn 1991;14:S17.
26. Bult H, Fret HRL, Jordeans FH, Herman AG. Dipyridamole potentiates the anti-aggregating and vasodilator activity of nitric oxide. Eur J Phramacol 1991;199:1-8.
27. Czernin J, Muller P, Chan S, et al. Influence of age and hemodynamics on myocardial blood flow and flow reserve. Circulation 1993;88:62-69.
28. Seiler C, Hess OM, Buechi H, Suten TM, Krayenbuehl HP. Influence of serum cholesterol and other coronary risk factors on vasomotion of angiographically normal coronary arteries. Circulation 1993;88:2139-2148.
29. Gould KL, Martucci JP, Goldberg DI, et al. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium. Circulation 1994;89:1530-1538.